Skip to main content

Table 3 General features of study with relapsing polychondritis

From: Demographic, clinical, treatment, outcome, and comorbidities of patients with relapsing polychondritis: experience from Brazilian tertiary center, and literature review

Authors Ref

Year

Study

Cases

(n)

Age at RP diagnosis (years)

F: M ratio

Auricular chondritis (%)

Arthralgia (%)

Arthritis (%)

Septum nasal chondritis (%)

Nasal bridge (%)

Hearing loss (%)

Ocular involvement (%)

Uveitis (%)

Episcleritis (%)

Laryngeal involvement (%)

Tracheobronchial (%)

Laryngotracheitis (%)

Costochondritis (%)

Subglottic stenosis (%)

Vestibular involvement (%)

Neurological involvement (%)

Cardiac involvement (%)

Renal involvement (%)

Current study

2024

Brazil

47

40

1.4:1

87.2

53.2

34

36.2

10.6

27.7

46.8

29.8

17

10.6

34.0

31.9

21.3

14.9

10.6

10.6

2.1

2.1

Zeuner et al. [20]

1997

Deutschland

62

46.6

0.7:1

93.5

-

-

56.5

-

-

49

-

-

-

-

-

2.3

-

-

9.7

-

7.9

Ernst et al. [8]

2009

USA

145

-

-

-

-

-

35.2

-

-

32.5

-

-

-

-

-

-

5.5

-

-

-

-

Shimizu et al. [2]

2015

Japan

239

52.7

0.9:1

78.2

-

-

-

39.3

61.7

46.1

-

-

-

-

-

-

-

-

9.6

7.1

9.2

Shimizu et al. [15]

2015

Japan

239

52.7

0.9:1

78

-

-

15.3

-

-

-

-

-

-

-

-

19.4

-

-

-

-

-

Lin et al. [4]

2016

China

158

45.3

0.7:1

68

-

56

-

-

25

44

-

-

-

-

69

15

-

-

-

-

3

Horváth et al. [5]

2016

Hungary

233

-

1:1

-

-

-

-

-

-

57.3

-

-

-

-

-

-

-

-

-

-

-

Dion et al. [17]

2016

France

142

-

1.7:1

89

66.2

33.1

-

-

27

56

13

36

43

22

-

40

-

-

-

-

-

Ferrada et al. [18]

2018

USA

304

43,2

6.4:1

86

-

-

63

-

34

53

-

-

-

74

-

-

15

-

-

-

-

Shimizu et al. [24]

2018

Japan

239

-

0.9:1

-

-

-

39

-

-

-

-

-

-

-

-

-

-

-

9.6

-

6.7

Zhang et al. [19]

2019

China

87

45.9

1.7:1

57.5

-

14.9

16.1

-

9.2

50

-

-

-

-

42.5

47

-

-

1.1

-

6.5

Shimizu et al. [21]

2020

Japan

229

-

0.9:1

-

-

-

40

-

-

-

-

-

-

-

-

-

-

-

12

-

-

Chen et al. [3]

2021

China

295

41

1:1

-

40

-

-

-

-

-

-

-

-

-

-

-

-

-

12

-

-

Zhang et al. [9]

2021

China

126

47.1

0.9:1

59.6

-

12.7

-

-

9.5

47

-

-

13.5

38.1

-

2.4

-

-

-

-

-

Cao et al. [12]

2021

China

181

-

0.8: 1

83.2

-

-

61.9

-

-

34.8

-

-

-

-

77.3

58

-

-

3.2

-

-

Ferrada et al. [16]

2021

USA

73

43

5.6:1

14

-

-

39

-

26

-

-

-

-

-

-

-

-

-

12

-

-

Ferrada et al. [26]

2021

USA

85

-

5.5:1

-

-

91

84

-

29

-

-

-

-

-

-

85

-

-

-

-

-

Nakajima et al. [10]

2022

-

117

43.2

2.3:1

78.6

-

-

47.9

-

-

19.8

-

-

-

59.9

-

-

-

-

4.8

-

-

Shimizu et al. [11]

2022

Japan

190

-

0.9:1

-

-

-

26.3

-

-

43.2

-

-

-

-

-

-

-

-

45

-

7.9

Wang et al. [13]

2022

China

72

55.2

0.7:1

62.4

-

8.3

-

-

-

-

-

-

11.1

-

-

-

-

-

-

-

-

Sangle et al. [6]

2023

Great Britain

68

48

2.1:1

58.8

-

20

-

15

20.6

-

-

-

-

-

73.5

-

5.9

-

-

-

-

Handa et al. [7]

2023

Japan

77

-

1.2:1

22.1

-

60.3

64.7

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Luo et al. [22]

2023

USA

66

38

3.3:1

64

-

-

76

-

-

24

-

-

-

-

-

-

-

-

-

-

-

Yi et al. [23]

2023

China

52

48

0.6:1

-

-

-

-

-

-

-

-

-

-

-

-

42

-

-

-

-

-

Yin et al. [25]

2023

China

187

-

1:1

-

48.4

-

56.3

-

-

58.4

-

-

47.9

79.2

-

-

-

-

14.2

-

2.5

Yin et al. [27]

2023

China

146

-

-

21.9

41.8

-

-

-

16.8

18.9

-

-

-

-

-

-

-

-

4.9

-

1.2

Back to article page

Advances in Rheumatology

ISSN: 2523-3106